Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib versus NP chemotherapy as adjuvant therapy after radical resection in EGFR-mutant stage IIIA NSCLC
ChiCTR-TRC-12002466Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 1990
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib, vinorelbine and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 2-year disease-free survival rate. Started Jan 1990; status: completed.
02
Drugs
erlotinibvinorelbinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-12002466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002466.